Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
American Society of Hematology
2018
|